Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. (KRYS) Healthcare & Pipeline Overview

Krystal Biotech, Inc. is a clinical-stage biotechnology firm pioneering redosable gene therapies for serious rare diseases. Focused on addressing unmet medical needs, its lead candidate, B-VEC, is in Phase III for dystrophic epidermolysis bullosa, supported by a diverse pipeline targeting genetic skin conditions, cystic fibrosis, and aesthetic applications.

What Is the Investment Thesis for KRYS?

Krystal Biotech, Inc. presents a research focus centered on its advanced gene therapy pipeline, particularly the lead candidate, beremagene geperpavec (B-VEC), which is in a pivotal Phase III clinical study for dystrophic epidermolysis bullosa. Successful commercialization of B-VEC represents a significant value driver, addressing a rare disease with substantial unmet medical needs. The company's robust gross margin of 92.8% and profit margin of 53.9% reflect efficient operational management and potential for strong future profitability upon product approvals. The broader pipeline, including KB105 for ichthyosis and KB301 for aesthetic applications, offers multiple shots on goal, diversifying potential revenue streams beyond its lead program. With a market capitalization of $11.06B, investors appear to be factoring in the potential for significant future growth from its gene therapy platform. Key catalysts include clinical trial readouts, regulatory filings, and potential approvals for B-VEC and other pipeline assets. However, as a clinical-stage biotechnology company, the investment carries inherent risks associated with drug development, including trial failures, regulatory hurdles, and market adoption challenges.

Based on FMP financials and quantitative analysis

KRYS Key Highlights

• Market Capitalization of $11.06B, reflecting significant investor valuation for its gene therapy pipeline.
• Profit Margin of 53.9%, demonstrating strong profitability at its current operational scale.
• Gross Margin of 92.8%, indicating highly efficient cost management relative to its revenue generation.
• P/E Ratio of 33.9, suggesting investor expectations for substantial future earnings growth.
• Beta of 0.49, indicating lower historical volatility compared to the broader market index.

Who Are KRYS's Competitors?

KRYS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KRYS's Key Strengths?

• Advanced lead product candidate (B-VEC) in Phase III clinical study for a rare disease.
• Diverse pipeline addressing multiple rare genetic conditions and aesthetic applications.
• Proprietary redosable gene therapy platform, offering potential differentiation.
• Strong financial metrics with a 92.8% gross margin and 53.9% profit margin.
• Focus on diseases with high unmet medical needs, potentially leading to premium pricing and orphan drug benefits.

What Are KRYS's Weaknesses?

• Currently a clinical-stage company, lacking commercialized products and associated revenue streams.
• High reliance on successful clinical trial outcomes and regulatory approvals for future viability.
• Significant research and development expenses inherent in biotechnology, impacting profitability until commercialization.
• Limited geographic reach, primarily focused on the United States market as per description.
• Beta of 0.49, while indicating lower volatility, may also suggest less sensitivity to broader market uptrends.

What Could Drive KRYS Stock Higher?

• Completion and positive readout of the Phase III clinical study for beremagene geperpavec (B-VEC) in dystrophic epidermolysis bullosa.
• Submission of a Biologics License Application (BLA) or Marketing Authorization Application (MAA) for B-VEC to regulatory authorities.
• Advancement of KB105 from Phase I/II to a later-stage clinical trial for autosomal recessive congenital ichthyosis.
• Initial clinical data readouts or progression of KB301 in its Phase I/II study for aesthetic skin conditions.
• Continued progress and de-risking of preclinical programs, such as KB407 for cystic fibrosis and KB104 for Netherton syndrome, towards IND-enabling studies.

What Are the Key Risks for KRYS?

• Rich valuation — a P/E of 33.9 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
• Insider selling — insiders were net sellers of roughly $15.6M recently.
• Clinical trial failure for B-VEC or other pipeline candidates, which could result in significant delays or discontinuation of development.
• Regulatory approval risks, including delays, rejections, or stringent post-marketing requirements for its gene therapy products.
• Intense competition within the gene therapy and rare disease markets, potentially impacting market share or pricing power upon commercialization.
• Manufacturing and supply chain challenges inherent in producing complex gene therapies, affecting scalability and cost-effectiveness.
• Intellectual property disputes or challenges to patent validity, which could undermine the company's competitive position.

What Are the Growth Opportunities for KRYS?

• **Commercialization of Beremagene Geperpavec (B-VEC):** The most immediate and significant growth opportunity for Krystal Biotech lies in the successful commercialization of its lead product candidate, B-VEC, for dystrophic epidermolysis bullosa (DEB). As B-VEC is in Phase III clinical study, a positive outcome and subsequent regulatory approval would allow Krystal Biotech to enter the market with a novel gene therapy for a severe, rare genetic skin disorder with limited treatment options. The market for rare disease therapies often commands premium pricing, and successful launch could generate substantial revenue, establishing Krystal Biotech as a commercial-stage company. The timeline for this opportunity is contingent on clinical trial completion, regulatory review, and market access negotiations.
• **Advancement of KB105 for Autosomal Recessive Congenital Ichthyosis:** Krystal Biotech's KB105 program, currently in Phase I/II clinical study, targets autosomal recessive congenital ichthyosis (ARCI), another serious rare genetic skin disease. Successful progression through clinical development and eventual approval for KB105 would expand the company's therapeutic portfolio within rare dermatological conditions. This offers a distinct growth pathway by addressing a separate patient population with high unmet needs, leveraging the company's expertise in gene therapy delivery to the skin. The market for ARCI treatments, while niche, represents a significant opportunity for a first-in-class or best-in-class gene therapy.
• **Expansion into Aesthetic Dermatology with KB301:** The development of KB301, in Phase I/II clinical stage for wrinkles and other presentations of aged or damaged skin, represents a strategic diversification into the aesthetic market. This market is significantly larger than rare disease markets and could provide a broader revenue base. While highly competitive, a gene therapy approach for skin aesthetics could offer a differentiated, potentially longer-lasting solution compared to existing treatments. Successful development and commercialization of KB301 would open a new, high-volume market segment for Krystal Biotech, leveraging its gene therapy platform beyond rare diseases.
• **Progression of Preclinical Programs (KB407, KB104):** Krystal Biotech's preclinical pipeline, including KB407 for cystic fibrosis and KB104 for Netherton syndrome, offers long-term growth potential. Cystic fibrosis represents a large market with ongoing innovation, and a novel gene therapy could capture a significant share. Netherton syndrome, another rare genetic skin disorder, aligns with the company's core expertise. Successful advancement of these programs into clinical stages would validate the versatility of Krystal Biotech's platform and expand its addressable therapeutic areas, providing future revenue opportunities beyond its current clinical-stage assets. These opportunities are longer-term, typically spanning several years for clinical development.
• **Leveraging Discovery Stage Programs for Chronic Skin Diseases (KB5xx, KB3xx):** The company's discovery stage product candidates, such as KB5xx for chronic skin diseases and additional KB3xx products for aesthetic skin conditions, represent foundational opportunities for future pipeline expansion. These early-stage programs allow Krystal Biotech to explore new targets and indications, potentially leading to a continuous stream of innovative gene therapy candidates. Successful identification and development of these programs could unlock entirely new therapeutic franchises, ensuring sustained growth and market relevance in the long term by continuously replenishing the company's development pipeline and expanding its intellectual property portfolio. This represents a multi-year, strategic investment in future growth.

What Opportunities Does KRYS Have?

• Successful commercialization of B-VEC, establishing a revenue-generating product for dystrophic epidermolysis bullosa.
• Expansion into the aesthetic dermatology market with KB301, tapping into a larger commercial opportunity.
• Advancement of preclinical programs (KB407 for cystic fibrosis, KB104 for Netherton syndrome) into clinical stages.
• Potential for strategic partnerships or collaborations to accelerate development or expand market access.
• Leveraging the gene therapy platform to discover and develop treatments for additional chronic skin or rare systemic diseases.

What Threats Does KRYS Face?

• Clinical trial failures or unexpected adverse events for any pipeline candidates.
• Regulatory hurdles, delays in approval, or failure to obtain marketing authorization from health authorities.
• Intense competition from other biotechnology and pharmaceutical companies developing gene therapies or alternative treatments.
• Patent challenges or loss of intellectual property protection for its core technologies.
• Market adoption challenges, including pricing pressures, reimbursement issues, or physician reluctance to adopt new gene therapies.

What Are KRYS's Competitive Advantages?

• Proprietary redosable gene therapy platform, potentially offering a differentiated approach compared to single-administration therapies.
• Focus on rare diseases, which often benefit from orphan drug designations, providing market exclusivity and expedited regulatory pathways.
• Extensive clinical pipeline targeting multiple indications, diversifying therapeutic reach and reducing reliance on a single asset.
• Specialized expertise in gene therapy delivery to the skin, addressing dermatological conditions with high unmet medical needs.
• Intellectual property surrounding its gene therapy constructs and delivery mechanisms.

What Does KRYS Do?

Krystal Biotech, Inc., founded in 2015 and headquartered in Pittsburgh, Pennsylvania, is a clinical-stage biotechnology company dedicated to the development of redosable gene therapies for serious rare diseases within the United States. The company's innovative approach centers on leveraging its proprietary gene therapy platform to address conditions with significant unmet medical needs. Its flagship product candidate, beremagene geperpavec (B-VEC), is currently undergoing a pivotal Phase III clinical study for the treatment of dystrophic epidermolysis bullosa, a severe genetic skin disorder. This advanced stage program represents a critical focus for the company's near-term strategic objectives. Beyond B-VEC, Krystal Biotech maintains a robust and diversified pipeline. This includes KB105, which is in Phase I/II clinical study for patients with deficient autosomal recessive congenital ichthyosis, another rare genetic skin condition. The company is also exploring broader applications of its technology, exemplified by KB301, currently in Phase I/II clinical stage for addressing wrinkles and other presentations of aged or damaged skin, indicating potential expansion into the aesthetic dermatology market. Further preclinical programs include KB407 for cystic fibrosis, a severe respiratory disease, and KB104 for Netherton syndrome, another rare genetic skin disorder. Additionally, Krystal Biotech's discovery stage portfolio features candidates like KB5xx for chronic skin diseases and multiple KB3xx products aimed at aesthetic skin conditions, underscoring its long-term commitment to expanding its therapeutic reach and platform utility across various dermatological and systemic indications. The company's strategic positioning as a clinical-stage entity with a focus on redosable gene therapy distinguishes its approach in the competitive biotechnology landscape, aiming to provide durable and effective treatments for patients.

What Products and Services Does KRYS Offer?

• Develops redosable gene therapies for serious rare diseases.
• Focuses on genetic skin disorders, including dystrophic epidermolysis bullosa (DEB) and autosomal recessive congenital ichthyosis (ARCI).
• Has a lead product candidate, B-VEC, in Phase III clinical study for DEB.
• Is developing KB105 for ARCI, currently in Phase I/II clinical study.
• Explores gene therapy for aesthetic applications, with KB301 in Phase I/II for aged or damaged skin.
• Conducts preclinical research for treatments for cystic fibrosis (KB407) and Netherton syndrome (KB104).
• Maintains discovery stage programs for chronic skin diseases (KB5xx) and additional aesthetic skin conditions (KB3xx).
• Operates as a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania.

How Does KRYS Make Money?

• Primarily focused on research and development of gene therapies, with future revenue generation anticipated from product sales upon regulatory approval.
• Aims to commercialize its lead candidate, B-VEC, for dystrophic epidermolysis bullosa, targeting a rare disease market with high unmet needs.
• Seeks to expand its product portfolio through the advancement of its diverse pipeline, including therapies for other rare genetic conditions and aesthetic indications.
• Potential for licensing agreements or partnerships for certain pipeline assets or geographic markets, though not explicitly stated in provided data.
• Relies on successful clinical trial outcomes and regulatory approvals to transition from a clinical-stage to a commercial-stage biotechnology company.

What Industry Does KRYS Operate In?

Krystal Biotech, Inc. operates within the highly specialized and rapidly evolving biotechnology industry, specifically focusing on gene therapy for rare diseases. This segment of healthcare is characterized by significant research and development investment, high regulatory hurdles, and the potential for substantial market impact due to addressing unmet medical needs. The broader gene therapy market is experiencing robust growth, driven by scientific advancements and increasing regulatory approvals for innovative treatments. Krystal Biotech positions itself by developing 'redosable' gene therapies, a potential differentiator in a field where single-administration treatments are common. The competitive landscape includes established pharmaceutical companies and numerous emerging biotechs also pursuing gene therapy solutions for various indications. Krystal Biotech's focus on rare dermatological conditions, such as dystrophic epidermolysis bullosa and ichthyosis, places it in a niche with high barriers to entry but also potentially expedited regulatory pathways and premium pricing opportunities, if successful.

Who Are KRYS's Key Customers?

• Patients suffering from dystrophic epidermolysis bullosa (DEB) upon B-VEC approval.
• Patients with deficient autosomal recessive congenital ichthyosis (ARCI) if KB105 is approved.
• Individuals seeking treatments for wrinkles and aged/damaged skin if KB301 is approved.
• Healthcare providers (dermatologists, geneticists, pulmonologists) who would prescribe and administer the therapies.
• Hospitals and specialized treatment centers that would procure and utilize Krystal Biotech's gene therapies.

Net sellingInsider Activity

Over the past six months, Krystal Biotech, Inc. insiders filed 23 SEC Form 4 transactions — 23 sales and 0 purchases. On net that is roughly 51K shares disposed (about $15.6M), a signal worth weighing alongside the fundamentals.

KRYS Valuation & Market Position

With a $11.06B market cap, Krystal Biotech, Inc. sits in the large-cap segment of the market. Relative to its peer group, KRYS's quantitative score of 100/100 is above the peer average of 50/100.

ROE 19%Key Financial Metrics

Return on equity for Krystal Biotech, Inc. stands at 19.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.1%, showing how much profit it generates from its asset base. KRYS trades at a trailing price-to-earnings ratio of 33.89, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Krystal Biotech, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 56.80 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Krystal Biotech, Inc. revenue of about $519.2M for fiscal 2026, with EPS near $7.67. The estimate reflects 6 contributing analysts.

Company Profile

Krystal Biotech, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Pittsburgh, US. The company is led by CEO Krish S. Krishnan. KRYS has traded publicly since 2017.

KRYS Financials

KRYS Latest News

KRYS Analyst Consensus

KRYS MoonshotScore

Latest Krystal Biotech, Inc. Analysis

Krystal Biotech, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources